Physician profile
Payam Amini
NPI 1205036456
$11,447.59
in general payments reported to CMS, 2019-2025
38 companies · $994 in 2025
The $994 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,026 · 2020: $407 · 2021: $1,060 · 2022: $3,212 · 2023: $3,374 · 2024: $1,376 · 2025: $994.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,399 · Consulting Fee: $2,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,398.62 |
| Consulting Fee | $2,345.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech, INC. | $2,539.32 | 2019-2025 | Susvimo |
| Eyepoint US, INC. | $2,173.46 | 2019-2023 | |
| Allergan, INC. | $1,243.42 | 2019-2022 | |
| Astellas Pharma US INC | $676.05 | 2023-2025 | Izervay |
| Bausch & Lomb Americas INC. | $633.47 | 2022-2024 | Stellaris, Miebo, Xiidra |
| Ivantis, INC | $529.74 | 2021 | |
| Alcon Vision LLC | $435.68 | 2019-2025 | Clareon, Argos, Tryptyr |
| Regeneron Healthcare Solutions, INC. | $388.04 | 2019-2023 | Eylea Hd |
| Genentech USA, INC. | $335.87 | 2021-2025 | Vabysmo |
| Dompe US, INC. | $315.59 | 2022-2025 | Oxervate |
| Abbvie INC. | $310.39 | 2023-2025 | Ozurdex |
| Regeneron Pharmaceuticals, INC. | $293.64 | 2022-2025 | Eylea, Eylea Hd |
| Alimera Sciences, INC. | $180.28 | 2023 | Iluvien |
| Samsara Vision | $160.54 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $158.73 | 2019-2023 | Catalys System |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $150.90 | 2022-2024 | Tyrvaya |
| Apellis Pharmaceuticals, INC. | $137.81 | 2022-2023 | Syfovre |
| Ocular Therapeutix, INC. | $131.33 | 2024 | Dextenza |
| Sun Pharmaceutical Industries INC. | $131.11 | 2019-2024 | |
| Eyevance Pharmaceuticals LLC | $89.79 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $89.22 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $84.43 | 2024-2025 | Purified Cortrophin Gel, Yutiq |
| Thea Pharma INC. | $77.69 | 2022-2024 | Iyuzeh |
| Aerie Pharmaceuticals, INC. | $59.40 | 2020-2021 | |
| Glaukos Corporation | $32.48 | 2025 | |
| Horizon Therapeutics Plc | $24.26 | 2021 | |
| Spark Therapeutics, INC. | $19.51 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $16.75 | 2025 | Xdemvy |
| Harrow Eye, LLC | $14.80 | 2025 | Vevye |
| Optos, INC. | $13.06 | 2022 | |
| Travere Therapeutics, INC. | $0.83 | 2021 |
7 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Payam Amini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.